Cancer Research and Treatment

Second-Line Chemotherapy for Advanced Non-small Cell Lung Cancer: Past, Present, and Hope for the Future: Keunchil Park; Cancer Res Treat. 2003;35(4):279-280. Published online August 31, 2003; DOI: https://doi.org/10.4143/crt.2003.35.4.279

Abstract PDF

No abstract available.

Citations

Citations to this article as recorded by

Positive expression of ERCC1 predicts a poorer platinum-based treatment outcome in Chinese patients with advanced non-small-cell lung cancer
Xin Wang, Jun Zhao, Lu Yang, Li Mao, Tongtong An, Hua Bai, Shuhang Wang, Xuyi Liu, Guoshuang Feng, Jie Wang
Medical Oncology.2010; 27(2): 484. CrossRef
Clinical Significance of Vascular Endothelial Growth Factors (VEGF)-C and -D in Resected Non-Small Cell Lung Cancer
Yoon Ho Ko, Chan-Kwon Jung, Myung-Ah Lee, Jae Ho Byun, Jin Hyoung Kang, Kyo Young Lee, Keon Hyun Jo, Young Pil Wang, Young Seon Hong
Cancer Research and Treatment.2008; 40(3): 133. CrossRef
Gefitinib (ZD1839): Therapy in selected patients with non-small cell lung cancer (NSCLC)?
Diego Dongiovanni, Lorenzo Daniele, Carla Barone, Vincenzo Dongiovanni, Camilla Fissore, Anna Sapino, Luigia Macrì, Giovanni Bussolati, Lucio Buffoni, Fabio Gaspari, Raffaella Grillo, Nadia Birocco, Alfredo Addeo, Libero Ciuffreda, Marina Schena
Lung Cancer.2008; 61(1): 73. CrossRef
Gefitinib (ZD1839) Monotherapy as a Salvage Regimen for Previously Treated Advanced Non-Small Cell Lung Cancer
Jinny Park, Byung Bae Park, Jee Youn Kim, Se-Hoon Lee, Soon Il Lee, Ho Young Kim, Jung Han Kim, Se Hoon Park, Kyung-Eun Lee, Joon Oh Park, Kihyun Kim, Chul Won Jung, Young Suk Park, Young-Hyuck Im, Won Ki Kang, Mark H. Lee, Keunchil Park
Clinical Cancer Research.2004; 10(13): 4383. CrossRef

3,503 View
15 Download
4 Crossref

Advances in Nuclear Oncology: E Edmund Kim; Cancer Res Treat. 2003;35(4):281-288. Published online August 31, 2003; DOI: https://doi.org/10.4143/crt.2003.35.4.281

Abstract PDF: No abstract available.

2,944 View
16 Download

Microsatellite Alterations in Serum DNA of Lung Cancer Patients: Sang Cheul Oh, Young Do Yoo, So Young Yoon, Seok Jin Kim, Jae Hong Seo, Kwang Taek Kim, Sang Won Shin, Yo Han Kim, Yeul Hong Kim, Jun Suk Kim; Cancer Res Treat. 2003;35(4):289-293. Published online August 31, 2003; DOI: https://doi.org/10.4143/crt.2003.35.4.289

Abstract PDF: No abstract available.

4,276 View
19 Download

Phase II Study of Gemcitabine and Vinorelbine as Second-Line Chemotherapy in Non-Small Cell Lung Cancer: Yoon Jae Kim, Joo Hyuk Sohn, Chul Kim, Yong Tai Kim, Hai Jin Kim, Joong Bae Ahn, Se Kyu Kim, Joon Chang, Nae Choon Yoo, Joo Hang Kim, Jae Yong Cho; Cancer Res Treat. 2003;35(4):294-298. Published online August 31, 2003; DOI: https://doi.org/10.4143/crt.2003.35.4.294

Abstract PDF: PURPOSE
With the increased use of chemotherapy for non small cell lung cancer (NSCLC), a growing group of patients can now be considered for second-line chemotherapy. However, guidelines for the second line treatment remain to be developed. The objective of this study was to evaluate the efficacy and safety of the gemcitabine and vinorelbine combination therapy in patients with advanced NSCLC, pretreated with taxane and platinum based regimens. Gemcitabine has already demonstrated activity in this patient group, with the combination therapy having been reported to be well tolerated in previous phase I/II studies.
MATERIALS AND METHODS
Forty two patients with advanced NSCLC (stages III/IV), having received prior taxane and platinum based chemotherapy, with an ECOG performance status (PS) 0~2, and unimpaired hematopoietic and organ function, were treated with vinorelbine, 20 mg/m2, followed by gemcitabine, 1, 000 mg/m2, both administered on days 1, 8 and 15, every 4 weeks.
RESULTS
Out of the 42 patients enrolled, 41 were evaluable for their response, and all 42 for their toxicity. The patient's characteristics were as follows; median age=60 years (42~73), median PS=1 (range 0~2), a gender ratio 31: 11 males/females, with stages IIIA, IIIB and IV in 3, 14 and 25 cases. The objective responses included a partial response (PR) 8/41 (19.5%), a stable disease 15/41 (36.6%) and a progressive disease 18/41 (43.9%). The median time-to progression (TTP) and survival were 4 months, ranging from 2 to 14 months, and 8 months, ranging from 2 to 17+ months, respectively. Grade 3 neutropenia was seen in 19% of the patient, and there was no grade 4 neutropenia or episodes of febrile neutropenia. No grade 4 thrombocytopenia or other grade 3/4 non-hematological toxicities were observed.
CONCLUSION
The combination of gemcitabine/vinorelbine is active and well tolerated in patients with advanced NSCLC having failed prior taxane/platinum therapy.

4,212 View
30 Download

Effect of Combination Chemotherapy with Docetaxel Plus Cisplatin in Patients with Advanced Non-Small Cell Lung Cancer: Hee Jung Kang, Min Kyoung Kim, Young Gil Kim, Jae Lyun Lee, Kyung Hee Lee, Myung Soo Hyun, Sung Hwa Bae, Hun Mo Ryoo; Cancer Res Treat. 2003;35(4):299-303. Published online August 31, 2003; DOI: https://doi.org/10.4143/crt.2003.35.4.299

Abstract PDF: PURPOSE
This study was conducted to evaluate the efficacy and safety of combination chemotherapy, with docetaxel and cisplatin, as a first line treatment for advanced non-small cell lung cancer.
MATERIALS AND METHODS
Between March 1998 and December 2001, 35 patients with advanced non-small cell lung cancer were enrolled in this study. The patients were treated at 3-week intervals, with one course of a regimen consisting of docetaxel (75 mg/m2 IV for 1 hours) on day 1 and cisplatin (60 mg/m2 IV) on day 2.
RESULTS
The median age of the patients was 60.3 years. Of the 35 patients, 20 and 15 had stage IIIb and stage IV diseases, respectively. A complete response was observed in 1 patient and partial response in 15, with an overall response rate of 46%. The overall median survival duration was 40.3+/-25.2 weeks. The median time to progression and response duration were 21.6+/-5.5 and 15.1+/-5.9 weeks, respectively. The survival duration was statistically significantly longer in the response group (50.6 weeks) than in the non-response group (31.6 weeks) (p<0.05). Of the hematological side effects, grades III and IV leukopenia were observed in 4.8% of patients. Grades III and IV nausea and vomiting were observed in 48.5%, and grades I and II neuropathy in 11.4% of the treated patients. These toxicities were well tolerable and reversible. There were no hypersensitivity reactions.
CONCLUSION
Docetaxel and cisplatin combination chemotherapy is relatively effective and safe in advanced non-small cell lung cancer patients.

4,175 View
34 Download

New Approaches to Functional Process Discovery in HPV 16-Associated Cervical Cancer Cells by Gene Ontology: Yong Wan Kim, Min Je Suh, Jin Sik Bae, Su Mi Bae, Joo Hee Yoon, Soo Young Hur, Jae Hoon Kim, Duck Young Ro, Joon Mo Lee, Sung Eun Namkoong, Chong Kook Kim, Woong Shick Ahn; Cancer Res Treat. 2003;35(4):304-313. Published online August 31, 2003; DOI: https://doi.org/10.4143/crt.2003.35.4.304

Abstract PDF

No abstract available.

Citations

Citations to this article as recorded by

BAG3 down-modulation sensitizes HPV18+ HeLa cells to PEITC-induced apoptosis and restores p53
Roberta Cotugno, Anna Basile, Elena Romano, Dario Gallotta, Maria Antonietta Belisario
Cancer Letters.2014; 354(2): 263. CrossRef
Expression Profiling of the Cellular Processes in Uterine Leiomyomas: Omic Approaches and IGF-2 Association with Leiomyosarcomas
Su Mi Bae, Yong-Wan Kim, Joon Mo Lee, Sung Eun Namkoong, Chong Kook Kim, Woong Shick Ahn
Cancer Research and Treatment.2004; 36(1): 31. CrossRef

4,349 View
19 Download
2 Crossref

Alterations in Promoter Usage and Expression Levels of Insulin-like Growth Factor-II and H19 Genes in Cervical and Endometrial Cancer: Chan Lee, Seung Jo Kim, Joong Yol Na, Chang Suk Park, Sun Young Lee, In Ho Kim, Yu Kyoung Oh; Cancer Res Treat. 2003;35(4):314-322. Published online August 31, 2003; DOI: https://doi.org/10.4143/crt.2003.35.4.314

Abstract PDF

PURPOSE
The biallelic expression of insulin-like growth factor-II (IGF2) and H19 has been reported to be associated with the progression of several tumors. Here, the promoter usage and expression levels of IGF2 and H19 are reported to be altered in cervical and endometrial cancers showing loss of imprinting (LOI).
MATERIALS AND METHODS
The imprinting status of IGF2 and H19 was examined in 32 cervical carcinomas, their matched normal tissues, 13 endometrial cancer and 33 normal endometrial tissues.
RESULTS
The LOI of IGF2 was observed in 7 of 18 (39%) and 1 of 13 (8.3%) informative cervical carcinomas and informative endometrial cancers, respectively. The LOI of the H19 gene was detected in 5 of 14 (36%) and in all 11 (100%) informative cervical carcinoma cases and informative endometrial cancer cases, respectively. The use of promoter P1 was observed in the LOI tumors of IGF2, but not in the tumors showing maintenance of IGF2 imprinting (MOI), or in cervical and endometrial cancers. Unlike MOI tumors, some LOI tumors revealed a lack of IGF2 transcription from the promoter P3. The LOI tumors of IGF2 showed increased expression of the IGF2 level, but a down-regulation of the H19, relative to normal tissues, whereas the MOI tumors revealed no significant alterations.
CONCLUSION
These results suggest that the promoter P1 could be involved in the biallelic expression of IGF2, and that the altered expression of the IGF2 and H19 levels might be associated with the progression of cervical and endometrial cancers that exhibit biallelic IGF2 expression.

Citations

Citations to this article as recorded by

Long Noncoding RNA Mediated Regulation in Human Embryogenesis, Pluripotency, and Reproduction
Lei Liu, Fang Fang, Xinyi Lu
Stem Cells International.2022; 2022: 1. CrossRef
Adherence to Cancer Prevention Guidelines and Endometrial Cancer Risk: Evidence from a Systematic Review and Dose-Response Meta-analysis of Prospective Studies
Hui Sun, Qing Chang, Ya-Shu Liu, Yu-Ting Jiang, Ting-Ting Gong, Xiao-Xin Ma, Yu-Hong Zhao, Qi-Jun Wu
Cancer Research and Treatment.2021; 53(1): 223. CrossRef
The Role of Long Non-Coding RNAs (lncRNAs) in Female Oriented Cancers
Faiza Naz, Imran Tariq, Sajid Ali, Ahmed Somaida, Eduard Preis, Udo Bakowsky
Cancers.2021; 13(23): 6102. CrossRef
Deregulation of H19 is associated with cervical carcinoma
Anirban Roychowdhury, Sudip Samadder, Pijush Das, Dipanjana Indra Mazumder, Ankita Chatterjee, Sankar Addya, Ranajit Mondal, Anup Roy, Susanta Roychoudhury, Chinmay Kumar Panda
Genomics.2020; 112(1): 961. CrossRef
PIM protein kinases regulate the level of the long noncoding RNA H19 to control stem cell gene transcription and modulate tumor growth
Neha Singh, Sathish K. R. Padi, Jeremiah J. Bearss, Ritu Pandey, Koichi Okumura, Himisha Beltran, Jin H. Song, Andrew S. Kraft, Virginie Olive
Molecular Oncology.2020; 14(5): 974. CrossRef
An updated review of the H19 lncRNA in human cancer: molecular mechanism and diagnostic and therapeutic importance
Behnam Alipoor, Seyedeh Nasrin Parvar, Zolfaghar Sabati, Hamid Ghaedi, Hassan Ghasemi
Molecular Biology Reports.2020; 47(8): 6357. CrossRef
Advances of Long Noncoding RNAs-mediated Regulation in Reproduction
Kang-Sheng Liu, Tai-Ping Li, Hua Ton, Xiao-Dong Mao, Ya-Jun Chen
Chinese Medical Journal.2018; 131(2): 226. CrossRef
Dysregulated expression of long noncoding RNAs in gynecologic cancers
Elahe Seyed Hosseini, Matthieu Meryet-Figuiere, Hamed Sabzalipoor, Hamed Haddad Kashani, Hossein Nikzad, Zatollah Asemi
Molecular Cancer.2017;[Epub] CrossRef

4,591 View
35 Download
8 Crossref

Prognostic Significance of KAI-1 and Survivin Expressions in Ovarian Epithelial Carcinomas: Ju Han Lee, Suk Min Lee, Jong Sang Choi; Cancer Res Treat. 2003;35(4):323-329. Published online August 31, 2003; DOI: https://doi.org/10.4143/crt.2003.35.4.323

Abstract PDF: PURPOSE
The purpose of this study was to evaluate the expressions of KAI-1 and survivin, and to investigate their correlation with the clinical stage and survival rate of patients with ovarian carcinomas.
MATERIALS AND METHODS
The expressions of survivin and KAI-1 were immunohistochemically determined in 54 serous and mucinous ovarian adenocarcinomas and borderline malignancy tumors. 10 of the 54 cases were also analyzed for the expressions of survivin and KAI-1 using western blot.
RESULTS
The down-regulation of the expression of KAI-1 was observed by immunohistochemical staining (IHC) in 53.7% of the ovarian cancers, and a negative reaction in 50% by the western blot analysis. From the IHC, the survivin expression was positive and strongly positive in 51.9 and 18% of the ovarian cancers, respectively. From the western blot analysis, 10% of the ovarian cancer showed positive reactions. The down- regulation of the KAI-1 expression was significantly correlated with the clinical stage (p=0.001) and disease free survival rate (p<0.001), but not with the histological type. The expression of survivin was not correlated with the clinical stage or histological type. However, the patients with a negative survivin expression had a significantly longer disease survival rate than those with a strong positive expression.
CONCLUSION
The down- and up-regulation of the KAI-1 and survivin, respectively, might be independent prognostic factors in human ovarian carcinomas.

3,414 View
28 Download

Concurrent FP (5-fluorouracil, cisplatin) Chemoradiotherapy for Patients with Esophageal Cancer: Min Ok Kim, Eui Sil Hong, Ji Young Chai, Joung Muk Leem, Il Young You, Won Dong Kim, Woo Yoon Park, Seung Taik Kim, Ki Hyeong Lee; Cancer Res Treat. 2003;35(4):330-334. Published online August 31, 2003; DOI: https://doi.org/10.4143/crt.2003.35.4.330

Abstract PDF

PURPOSE
The outcomes of a surgical approach for patients with an esophageal carcinoma remain unsatisfactory despite its high complication rates. We conducted a phase II trial, using combined FP (5-fluorouracil and cisplatin) chemotherapy and concurrent radiotherapy, as a definitive therapy for patients with esophageal cancer.
MATERIALS AND METHODS
Patients with histologically proven esophageal cancer were enrolled onto this study. The treatment consisted of four courses of chemotherapy and six and a half weeks of radiotherapy. The patients received chemotherapy in weeks 1, 5, 12 and 16 (5-fluorouracil 1, 000 mg/m2 on days 1 to 4 and cisplatin 75 mg/m2 on day 1). Radiotherapy was administered at a dose of 59.4 Gy, in five 1.8 Gy fractions a week.
RESULTS
A total of 22 eligible patients entered the study. Of the 19 evaluable patients, a complete response occurred in 7 (37%), and a partial response in 8 (42%). After a median follow-up of 35 months, the overall survival rate was 32% at three years and the median survival was 11 months. Fourteen (64%) received planned dose of radio-therapy and 13 (59%) received more than three courses of chemotherapy. However, there was no difference in three-year survival rates between the patients that received less than three courses of chemotherapy and those that received three or more courses (31% vs. 32%). The major treatment related toxicity was mucositis, which developed in every patient, with grades III or IV in thirteen (59%) patients. During the treatment, the patients lost, on average, 3.8% of their body weight. The mean hospital stay was 23 days, with a total duration of treatment of 74 days.
CONCLUSIONS
Concurrent FP chemoradiotherapy was effective as a definitive therapy for patients with esophageal cancer. The major toxicity was mucositis. Although the treatment was relatively feasible, a randomized trial of reduced courses of chemotherapy is warranted.

Citations

Citations to this article as recorded by

Anti-cancer Effects of a Novel Quinoline Derivative 83b1 on Human Esophageal Squamous Cell Carcinoma through Down-Regulation of COX-2 mRNA and PGE₂
Ivan Ho Yuen Pun, Dessy Chan, Sau Hing Chan, Po Yee Chung, Yuan Yuan Zhou, Simon Law, Alfred King Yin Lam, Chung Hin Chui, Albert Sun Chi Chan, Kim Hung Lam, Johnny Cheuk On Tang
Cancer Research and Treatment.2017; 49(1): 219. CrossRef
Bi-weekly Chemotherapy of Paclitaxel and Cisplatin in Patients with Metastatic or Recurrent Esophageal Cancer
Sang-Hee Cho, Ik-Joo Chung, Sang-Yun Song, Deok-Hwan Yang, Jeong-Rae Byun, Yeo-Kyeoung Kim, Je-Jung Lee, Kook-Joo Na, Hyeoung-Joon Kim
Journal of Korean Medical Science.2005; 20(4): 618. CrossRef

4,724 View
29 Download
2 Crossref

Clinical Significance of the Levels of Serum Cholesterol in Patients with Gastric Cancer: Tae Hyo Kim, Sung Jin Ahn, Woon Tae Jung, Ok Jae Lee, Woo Song Ha, Joung Soon Jang; Cancer Res Treat. 2003;35(4):335-340. Published online August 31, 2003; DOI: https://doi.org/10.4143/crt.2003.35.4.335

Abstract PDF

PURPOSE
The relationship between serum cholesterol levels and mortality is complex. Serum cholesterol levels correlate positively with coronary artery disease, but some studies have suggested a negative relationship in cancer patients. Because the serum cholesterol levels are one of the most frequently assayed laboratory values, trends in the levels of cholesterol were investigated, in patients with gastric cancer and assumed a possible role in cancer screening.
MATERIALS AND METHODS
The serum cholesterol levels were retrospectively analyzed in a group of 220 patients, diagnosed with gastric cancer, and in 177 healthy subjects. Anthropometric (body mass index: BMI) and biochemical indices of their nutritional status were also determined in the study subjects. Statistical analyses were performed by analyses of variance and covariance, and a discriminant analysis.
RESULTS
The levels of serum cholesterol, albumin, Hb and the BMI were significantly lower in the gastric cancer-patients group than in the healthy-subjects group. The serum cholesterol and Hb levels were shown to be independent of each other, when adjusted for the effects of the BMI. In the patients with gastric cancer the levels of cholesterol and Hb showed decreasing tendencies as did the tumor extension, as defined by the TNM system.
CONCLUSION
The serum cholesterol and Hb levels were significantly lower in patients with gastric cancer than in the healthy subjects, which seemed to be linked to the progression of gastric cancer. Therefore, further study is required for the serum cholesterol and Hb levels to be used as markers in cancer screening and its progression, in patients with gastric cancer.

Citations

Citations to this article as recorded by

Influence of cholesterol on cancer progression and therapy
Shyamananda Singh Mayengbam, Abhijeet Singh, Ajay D. Pillai, Manoj Kumar Bhat
Translational Oncology.2021; 14(6): 101043. CrossRef
Prognostic Importance of the Preoperative Naples Prognostic Score for Patients With Adenocarcinoma of the Esophagogastric Junction
Jianping Xiong, Yaqin Wang, Wenzhe Kang, Fuhai Ma, Hao Liu, Shuai Ma, Yang Li, Peng Jin, Haitao Hu, Yantao Tian
Frontiers in Oncology.2020;[Epub] CrossRef
Relationship between red blood cell distribution width, bilirubin, and clinical characteristics of patients with gastric cancer
T.‐T. Wei, L.‐L. Wang, J.‐R. Yin, Y.‐T. Liu, B.‐D. Qin, J.‐Y. Li, X. Yin, L. Zhou, R.‐Q. Zhong
International Journal of Laboratory Hematology.2017; 39(5): 497. CrossRef

4,087 View
35 Download
3 Crossref

TRAIL-Mediated Apoptosis in Human Liver Chang Cells: Channy Park, Sung Wook Hong, Sung Ho Jin, Nam Song Kim, Kyung Ho Cho, Jin Ho Cheon, Jae Yeon Ahn, Jung Ku Yang, Raekil Park; Cancer Res Treat. 2003;35(4):341-348. Published online August 31, 2003; DOI: https://doi.org/10.4143/crt.2003.35.4.341

Abstract PDF

PURPOSE
Tumor necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL)/APO-2L is a member of the TNF family that can kill a wide variety of tumor cells, but not normal cells. This study was designed to investigate the down stream target proteins in TRAIL-mediated apoptosis of human liver, Chang cells.
MATERIALS AND METHODS
The expressions of DR4/DR5 in hepatoma cells, including Chang, HepG2 and Hep3B cells, were determined by RT-PCR. Cell viability was measured by MTT assay and apoptosis was assessed by DNA fragmentation assay. The catalytic activity of caspase- family proteases, including caspase-3 and -9, was tested by using fluorogenic biosubstrates. Expression of apoptotic mediators, including procaspase-3 and PARP proteins, was measured by Western blotting. The expression profile of proteins in Chang cells by using two-dimensional (2-D) gel electrophoresis and MALDI-TOF.
RESULTS
The results demonstrated that TRAIL (100 ng/ml) induced the apoptotic death of Chang cells, as characterized by the ladder-pattern fragmentation of genomic DNA. TRAIL increased the enzymatic activity of caspase- 3, corresponding to the time of appearance of cleaved PARP and caspase-9. In 2-D gel electrophoresis and MALDI- TOF analysis, the comparison of control versus apoptotic cells in the protein expressions revealed that signal intensity of 7 spots were decreased, whereas 6 spots were increased among 300 spots. These spots were resolved and identified as a protein information by MALDI-TOF.
CONCLUSION
We suggested that TRAIL induces the apoptotic death of Chang cells via proteome alterations inducing caspase cascade.

Citations

Citations to this article as recorded by

Upregulation of NAD(P)H:Quinone Oxidoreductase By Radiation Potentiates the Effect of Bioreductive β-Lapachone on Cancer Cells
Eun K. Choi, Kaoru Terai, In-Mi Ji, Yeon H. Kook, Kyung H. Park, Eun T. Oh, Robert J. Griffin, Byung U. Lim, Jin-Seok Kim, Doo S. Lee, David A. Boothman, Melissa Loren, Chang W. Song, Heon Joo Park
Neoplasia.2007; 9(8): 634. CrossRef

4,793 View
23 Download
1 Crossref

Clinical Value of Whole Body F-18 FDG PET in The Management of Recurrent Colorectal Malignancy: Seok Byung Lim, Hyo Seong Choi, Sung Bum Kang, Seung Chul Heo, Young Jin Park, Seung Yong Jeong, Kyu Joo Park, Han Kwang Yang, Kyung Hoon Hwang, Jae Min Jeong, Dong Soo Lee, June Key Chung, Myung Chul Lee, Keon Wook Kang, Jae Gahb Park; Cancer Res Treat. 2003;35(4):349-354. Published online August 31, 2003; DOI: https://doi.org/10.4143/crt.2003.35.4.349

Abstract PDF: PURPOSE
The aim of this study was to evaluate the clinical value of whole body 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) in the patient with a recurrence of a previously treated colorectal malignancy.
MATERIALS AND METHODS
Fifty-eight cases were scanned using PET at the PET Center of Seoul National University Hospital between May 1995 and Aug 2002. All the patients had had a previous operation for a colorectal malignancy. The PET scans were performed for the following reasons: - investigation of a recurrence (n=12), investigation of the operability (n=38) and clinical follow up (n=8). In these 58 cases, 47 of the CT scans and 55 of the CEA (Carcinoembryonic antigen) were checked prior to the FDG- PET. The accuracy, sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of the PET scans were calculated, and compared with those of conventional CT scan and CEA, which were also compared with the previous reported data. Eight cases, whose managements were influenced by the PET findings, were analyzed.
RESULTS
Recurrences, or metastases, of colorectal cancer developed in 51 cases, with 49 of these being detected by the PET. The accuracy, sensitivity and specificity of the PET were 96.6 (56/58), 96.1 (49/51) and 100% (7/7), respectively. The PPV and NPV of the PET were 100 (49/49) and 77.8% (7/9), respectively. The accuracy and sensitivity of the PET were higher than those of the CT (85.1 and 88.1%), with the differences being statistically significant (p-value 0.001 and 0.003, respectively).
CONCLUSION
It is concluded that a FDG-PET scan is a more accurate and sensitive diagnostic tool than a CT scan for the detection of a recurrence or metastasis in a colorectal malignancy. In addition, a FDG-PET may alter the management of patients with recurrent colorectal cancer. Therefore, it is recommended that a PET should be considered when a tumor recurrence is suspected during conventional follow up.

4,105 View
28 Download

The Expressions of Cytokeratin 7 and 20 in Epithelial Tumors: A Survey of 91 Cases: Dong Hoon Kim, Jong Eun Joo, Eun Kyung Kim, Ho Jung Lee, Won Mi Lee; Cancer Res Treat. 2003;35(4):355-363. Published online August 31, 2003; DOI: https://doi.org/10.4143/crt.2003.35.4.355

Abstract PDF

PURPOSE
This study was performed to determine the expressions of cytokeratin 7 and cytokeratin 20 in epithelial neoplasms, and to investigate their potential role in the differential diagnosis of carcinomas of various organs.
MATERIALS AND METHODS
We investigated 91 various cases of primary and metastatic cancers, using a panel of commercially available monoclonal antibodies against cytokeratins 7 and 20 (CK7 and CK20), by immunohistochemistryand an avidin-biotin immunoperoxidase technique. The specimens were formalin-fixed and paraffin- embedded, and examined using 4micrometer thick serial sections.
RESULTS
The expression of CK7 was seen in the majority of carcinoma cases, including transitional cell carcinomas (100%), pulmonary adenocarcinomas (100%), ovarian serous adenocarcinomas (100%), cholangiocarcinomas (70%), colonic adenocarcinomas (64.29%) and invasive ductal carcinomas (60%). The expression of CK20 was seen in the majority of colorectal carcinomas cases (85.72%), but was virtually absent in pulmonary adenocarcinomas (0%), uterine cervical carcinomas (0%), ovarian carcinomas (0%), prostatic adenocarcinomas (0%), adenocarcinomas of the gall bladder (0%) and cholangiocarcinomas (12.5%).
CONCLUSION
In the all cases investigated, either CK7 or CK20 immunophenotypes were conserved in the tumor cells of primary tumors and in those of the corresponding metastatic lesions. It is suggested that CK7/CK20 immunophenotyping, in metastatic carcinomas of an unknown origin, maybe useful in the determination of the primary site of the metastasis.

Citations

Citations to this article as recorded by

Occult urothelial carcinoma with mediastinal metastasis: A case report
Jingfan Zheng, Xintong Peng, Xiaoqing Li, Yuyu Chen, Xinyi Li, Ling Fu, Ao Li, Zhong Lu
Oncology Letters.2024;[Epub] CrossRef
Cytomorphology, immunoprofile, and clinicopathologic correlation of metastatic prostatic carcinoma
Xiaoqi Lin, Qiuying Shi, Ximing J. Yang
Human Pathology.2022; 130: 36. CrossRef
Double cocktail immunostains with high molecular weight cytokeratin and GATA-3: useful stain to discriminate in situ involvement of prostatic ducts or acini from stromal invasion by urothelial carcinoma in the prostate
Junghye Lee, Youngeun Yoo, Sanghui Park, Min-Sun Cho, Sun Hee Sung, Jae Y. Ro
Journal of Pathology and Translational Medicine.2020; 54(2): 146. CrossRef

3,773 View
35 Download
3 Crossref

Metastatic Anaplastic Carcinoma of the Small Intestine Arising from The Lung: Dong Yi Kim, Jai Kyoon Joo, Seong Yeob Ryu, Young Jin Kim, Shin Kon Kim, Sang Woo Juhng; Cancer Res Treat. 2003;35(4):364-366. Published online August 31, 2003; DOI: https://doi.org/10.4143/crt.2003.35.4.364

Abstract PDF

A metastatic carcinoma of the small intestine is rare. Here, the case study of an 80-year-old lung carcinoma patient, with generalized peritonitis due to neoplastic perforation of the small intestine is reported. Pathological studies of a small intestinal mass revealed a metastatic anaplastic carcinoma arising from the lung. Patients with known lung carcinoma, who develop abdominal complaints, should be examined thoroughly. Although it is very difficult to diagnose and treat a metastatic carcinoma of the small intestine, in our judgment, with a greater awareness of this neoplasm, more cases may be diagnosed in the early stages, leading to improved rates of survival.

Citations

Citations to this article as recorded by

Metástasis gastrointestinales de carcinoma pulmonar primario. Serie de casos y revisión sistemática de la literatura
Andrea Balla, José D. Subiela, Jesús Bollo, Carmen Martínez, Carlos Rodriguez Luppi, Pilar Hernández, Yuliana Pascual-González, Silvia Quaresima, Eduard M. Targarona
Cirugía Española.2018; 96(4): 184. CrossRef
Gastrointestinal Metastasis From Primary Lung Cancer. Case Series and Systematic Literature Review
Andrea Balla, José D. Subiela, Jesús Bollo, Carmen Martínez, Carlos Rodriguez Luppi, Pilar Hernández, Yuliana Pascual-González, Silvia Quaresima, Eduard M. Targarona
Cirugía Española (English Edition).2018; 96(4): 184. CrossRef

3,543 View
29 Download
2 Crossref

Previous issues